Press coverage about Puma Biotechnology (NASDAQ:PBYI) has been trending somewhat positive on Monday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Puma Biotechnology earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 44.3016286949607 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Trader’s Focus- Puma Biotechnology, Inc. (PBYI) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Another motive To buy these stock: Puma Biotechnology, Inc., (NASDAQ: PBYI), Public Joint-Stock Company Mobile … – Stocks In The News (press release) (tradingnewsnow.com)
- Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings (finance.yahoo.com)
- Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) to Post -$2.04 Earnings Per Share (americanbankingnews.com)
- Puma (PBYI) Stock Up More than 200% This Year: Here’s Why (zacks.com)
Several research firms have weighed in on PBYI. BidaskClub cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 14th. Credit Suisse Group raised their price objective on shares of Puma Biotechnology from $136.00 to $142.00 and gave the company an “outperform” rating in a research report on Friday, November 10th. Barclays restated a “buy” rating and issued a $122.00 price objective (up previously from $103.00) on shares of Puma Biotechnology in a research report on Friday, November 10th. Citigroup raised their price objective on shares of Puma Biotechnology from $156.00 to $164.00 and gave the company a “buy” rating in a research report on Friday, November 10th. Finally, Royal Bank of Canada lowered their price objective on shares of Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating for the company in a research report on Friday, November 10th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $130.67.
Puma Biotechnology (NASDAQ:PBYI) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million during the quarter, compared to the consensus estimate of $3.78 million. During the same period last year, the business posted ($1.11) EPS. sell-side analysts expect that Puma Biotechnology will post -8.19 earnings per share for the current fiscal year.
In other news, SVP Richard Paul Bryce sold 15,000 shares of the firm’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $120.00, for a total value of $1,800,000.00. Following the transaction, the senior vice president now owns 42,239 shares of the company’s stock, valued at approximately $5,068,680. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Charles R. Eyler sold 1,322 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $105.46, for a total transaction of $139,418.12. The disclosure for this sale can be found here. 21.10% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Puma Biotechnology (PBYI) Earning Somewhat Favorable News Coverage, Study Shows” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.com-unik.info/2017/12/11/puma-biotechnology-pbyi-earning-somewhat-favorable-news-coverage-study-shows.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
What are top analysts saying about Puma Biotechnology Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Puma Biotechnology Inc and related companies.